The Cook Medical drug eluting peripheral stent proves a few solid results at 24 months in comparison with the data of one year.

Leipzig, Germany, February, 2011--the eluting stent drugs Zilver PTX of Cook Medical, available for the community health of the European Union, showed a consistent permeability initial two years of its implementation, in comparison with the first year, according to a random study presented at Leipzig Interventional Course. Data collected from 479 patients in a randomized trial showed that patients with this self-expanding nitinol stent and coated drug paclitaxel, presented an initial permeability of 83.1% at 12 months. When it became the test at 24 months, the rate of permeability in a poll 278 patients was 74.8 per cent. Data from the study showed that patients treated with Zilver PTX reached a survival rate of 86.6% in 24 months.

PAD, also known by the hardening ” the arteries or atherosclerosis occurs when deposits of fat and inflammation reduce blood flow in the lower extremities. The so-called Peripheral Arterial Disease suffer from it 27 million people in Europe and North America ¹. The test with the PTX Zilver trial confirms the safety and efficacy of the device of Cook for the treatment of severe complications in the superficial femoral artery.

The randomized study, the largest its kind that takes place at the global level, is complemented by a universe of 787 patients in several countries, which includes diabetics and patients with symptoms and complex injuries.

_
¹ Belch JJ, Topol EJ, Agnelli G, et to the. Critical issues in peripheral arterial disease detection and management: a call to action. Arch Intern Med. 2003; 163 (8): 884-892.

This trial has been rigorously designed to provide a real prospect the current treatment of Peripheral Arterial Disease worldwide, and we are very satisfied of the results has provided us with ”, said Rob Lyles, Global Chief and Vice President of the Division Peripheral Intervention, of Cook Medical. in Cook are committed in developing technologies to make progress in medicine, minimally invasive to the largest possible population ”.

About LINC

Leipzig Interventional Course is a course in international and exhaustive live designed to encourage collaboration among colleagues in different specialties and promote the understanding and development of therapies Endovascular that can be incorporated into the practical clinical daily.

About Cook Medical

founded in 1963, Cook Medical was the first company to implement much of the medical device to today used around the world in order to perform minimally invasive medical procedures in the human body. Currently, the company manufactures and markets medical devices, drugs and biological products employed in improving the safety and clinical outcomes of patients. Since its inception, Cook has operated as a private family-run company.